Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Aug:6:e2200138.
doi: 10.1200/PO.22.00138.

Constitutional Mosaicism: A Critical Issue in the Definition of BRCA-Inherited Cancer Risk

Affiliations

Constitutional Mosaicism: A Critical Issue in the Definition of BRCA-Inherited Cancer Risk

Elena Tenedini et al. JCO Precis Oncol. 2022 Aug.
No abstract available

PubMed Disclaimer

Conflict of interest statement

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/po/author-center.

Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).

Figures

FIG 1.
FIG 1.
Pedigree chart showing the tested patient and her family. In the diagram, the arrows indicate the patients who were tested in the different generations (roman numerals) and their age expressed in yo. *indicates same male subject. **indicates same pedigree diagram. mM/+, mosaic for mutation; M/+, heterozygous for mutation; +/+, no mutation; yo, years old.
FIG 2.
FIG 2.
Decisional algorithm to manage low VAF and interpret BRCA genetic test results in ovarian cancer. VAF, variant allele frequency.

References

    1. Pujol P, Barberis M, Beer P, et al. Clinical practice guidelines for BRCA1 and BRCA2 genetic testing. Eur J Cancer. 2021;146:30–47. - PubMed
    1. Gadducci A, Aletti GD, Landoni F, et al. Management of ovarian cancer: Guidelines of the Italian Medical Oncology Association (AIOM) Tumori. 2021;107:100–109. - PubMed
    1. Nero C, Ciccarone F, Pietragalla A, et al. Ovarian cancer treatments strategy: Focus on PARP inhibitors and immune check point inhibitors. Cancers (Basel) 2021;13:1298. - PMC - PubMed
    1. Weren RD, Mensenkamp AR, Simons M, et al. Novel BRCA1 and BRCA2 tumor test as basis for treatment decisions and referral for genetic counselling of patients with ovarian carcinomas. Hum Mutat. 2017;38:226–235. - PMC - PubMed
    1. Messina C, Cattrini C, Soldato D, et al. BRCA mutations in prostate cancer: Prognostic and predictive implications. J Oncol. 2020;2020:4986365. - PMC - PubMed